VEGFA and melanoma: Bevacizumab (Avastin, F. Hoffman-La Roche AG, Basel, CH) is a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF) approved for different cancers and studied with some preliminary results on advanced melanoma.